Systemic therapy is an essential part of treatment for all patients with small-cell lung cancer
(sclc) and for most patients with non-small-cell lung cancer (nsclc). Standards of care have …

Background Immune checkpoint inhibitors (ICIs) have shown unprecedented clinical benefit
in cancer immunotherapy and are rapidly transforming the practice of advanced lung cancer …

The treatment of advanced or refractory non–small cell lung cancer has been historically
difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer …

Non-small cell lung cancer (NSCLC) has been threatening human health for years.
Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment …

Immunotherapy is one of the methods that can change the survival rate of patients with
malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted …

Simple Summary The lung cancer treatment paradigm has been completely changed by
immunotherapy; however, less than half of the treated patients obtain a response, and an …

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of
cancer-related deaths worldwide. Although progress in the treatment of advanced non-small …

Immunotherapy in lung cancer treatment is a long history paved with failures and some
successes. During the last decade, the discovery of checkpoints inhibitors led to major …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …